Significance of hyponatremia in heart failure

Heart Failure Reviews

Volumn 17, Issue 1, 2012, Pages 17-26

  Bettari, Luca ^a   Fiuzat, Mona ^b   Felker, Gary M ^b   O'Connor, Christopher M ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Arginine vasopressin antagonists; Clinical trials; Heart failure; Hyponatremia; Outcomes

Indexed keywords

ARGININE VASOPRESSIN RECEPTOR ANTAGONIST; ARGIPRESSIN; CONIVAPTAN; LIXIVAPTAN; LOOP DIURETIC AGENT; PEPTIDE HORMONE ANTAGONIST; PLACEBO; SODIUM; SODIUM CHLORIDE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL MODEL; CONTINUOUS INFUSION; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; HYPONATREMIA; MORBIDITY; MORTALITY; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; REGISTER; RISK ASSESSMENT; RISK FACTOR; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; SURVIVAL; UNSPECIFIED SIDE EFFECT;

HEART FAILURE; HUMANS; HYPONATREMIA; MODELS, THEORETICAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASOPRESSIN;

EID: 84655165014     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-010-9193-3     Document Type: Article

References (65)

1. JJ McMurray MA Pfeffer 2005 Heart failure Lancet 365 9474 1877 1889 15924986 10.1016/S0140-6736(05)66621-4 (Pubitemid 40744967)
2. American Heart Association (2007) Heart disease and stroke statistics-2007 update. American Heart Association, Dallas
3. S Stewart A Jenkins S Buchan A McGuire S Capewell JJ McMurray 2002 The current cost of heart failure to the national health service in the UK Eur J Heart Fail 4 361 371 12034163 10.1016/S1388-9842(01)00198-2 (Pubitemid 35190362)
4. HM Krumholz EM Parent N Tu V Vaccarino Y Wang MJ Radford, et al. 1997 Readmission after hospitalization for congestive heart failure among medicare beneficiaries Arch Intern Med 157 e99 e104 10.1001/archinte.1997.00440220103013
5. W Rosamond K Flegal K Furie, et al. 2008 Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 117 4 e25 e146 18086926 10.1161/CIRCULATIONAHA.107.187998
6. HJ Adrogue NE Madias 2000 Hyponatremia N Engl J Med 342 1581 1589 10824078 10.1056/NEJM200005253422107 1:STN:280:DC%2BD3c3mslCqsQ%3D%3D (Pubitemid 30340505)
7. L De Luca L Klein JE Udelson C Orlandi G Sardella F Fedele M Gheorghiade 2005 Hyponatremia in patients with heart failure Am J Cardiol 96 19L 23L 16399089
8. M Gheorghiade WT Abraham NM Albert W Gattis Stough BH Greenberg CM O'Connor L She CW Yancy J Young GC Fonarow 2007 Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry Eur Heart J 28 980 988 17309900 10.1093/eurheartj/ehl542 1:CAS:528:DC%2BD2sXmslKqs7Y%3D (Pubitemid 47343897)
9. M Gheorghiade JS Rossi W Cotts DD Shin AS Hellkamp IL Pina GC Fonarow T DeMarco DF Pauly J Rogers TG DiSalvo J Butler JM Hare GS Francis WG Stough CM O'Connor 2007 Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial Arch Intern Med 167 1998 2005 17923601 10.1001/archinte.167.18.1998 (Pubitemid 47606641)
10. L Klein CM O'Connor JD Leimberger W Gattis-Stough IL Pina GM Felker KF Adams Jr RM Califf M Gheorghiade 2005 Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study Circulation 111 2454 2460 15867182 10.1161/01.CIR.0000165065.82609.3D 1:CAS:528:DC%2BD2MXjvFOju7c%3D (Pubitemid 40696133)
11. DA Sica 2005 Hyponatremia and heart failure-pathophysiology and implications Congest Heart Fail 11 274 277 16230871 10.1111/j.1527-5299.2005. 04180.x
12. MT Kearney KA Fox AJ Lee RJ Prescott AM Shah PD Batin W Baig S Lindsay TS Callahan WE Shell DL Eckberg AG Zaman S Williams JM Neilson J Nolan 2002 Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure J Am Coll Cardiol 40 1801 1808 12446064 10.1016/S0735-1097(02)02490-7 (Pubitemid 35341959)
13. M Senni R De Maria D Gregori L Gonzini M Gorini G Cacciatore A Gavazzi G Pulignano M Porcu AP Maggioni 2005 Temporal trends in survival and hospitalizations in outpatients with chronic systolic heart failure in 1995 and 1999 J Card Fail 11 270 278 15880335 10.1016/j.cardfail.2004.11.003 (Pubitemid 40616896)
14. RM Oren 2005 Hyponatremia in congestive heart failure Am J Cardiol 95 Suppl 2B 7B 15847851 10.1016/j.amjcard.2005.03.002 1:CAS:528: DC%2BD2MXksFGmur0%3D (Pubitemid 40545926)
15. Adhere Registry: Insights from the Adhere Registry: data from over 100,000 patient cases. 2005
16. S Kumar S Rubin PJ Mather DJ Whellan 2007 Hyponatremia and vasopressin antagonism in congestive heart failure Clin Cardiol 30 11 546 551 17847041 10.1002/clc.18 (Pubitemid 350209965)
17. M Gheorghiade WA Gattis CM O'Connor, et al. 2004 For the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial (ACTIV) JAMA 291 1963 1971 15113814 10.1001/jama.291.16.1963 1:CAS:528:DC%2BD2cXjs1ajsb8%3D (Pubitemid 38544277)
18. MA Konstam M Gheorghiade JC Burnett Jr L Grinfeld AP Maggioni K Swedberg JE Udelson F Zannad T Cook J Ouyang 2007 Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial JAMA 297 1319 1331 17384437 10.1001/jama.297.12.1319 1:CAS:528:DC%2BD2sXjs1ejtrg%3D (Pubitemid 46513233)
19. KD Aaronson JS Schwartz TM Chen KL Wong JE Goin DM Mancini 1997 Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation Circulation 95 12 2660 2667 9193435 1:STN:280:DyaK2szjs1Krug%3D%3D (Pubitemid 27255495)
20. DS Lee PC Austin JL Rouleau PP Liu D Naimark JV Tu 2003 Predicting mortality among patients hospitalized for heart failure derivation and validation of a clinical model JAMA 290 19 2581 2587 14625335 10.1001/jama.290.19.2581 1:CAS:528:DC%2BD3sXpt1Cmu7s%3D (Pubitemid 37443288)
21. MT Kearney J Nolan AJ Lee PW Brooksby R Prescott AM Shah AG Zaman DL Eckberg HS Lindsay PD Batin R Andrews KA Fox 2003 A prognostic index to predict long-term mortality in patients with mild to moderate chronic heart failure stabilised on angiotensin converting enzyme inhibitors Eur J Heart Fail 5 4 489 497 12921810 10.1016/S1388-9842(03)00053-9 1:CAS:528:DC%2BD3sXmt1Kitb0%3D (Pubitemid 37021643)
22. WC Levy D Mozaffarian DT Linker SC Sutradhar SD Anker AB Cropp I Anand A Maggioni P Burton MD Sullivan B Pitt PA Poole-Wilson DL Mann M Packer 2006 The Seattle heart failure model: prediction of survival in heart failure Circulation 113 1424 1433 16534009 10.1161/CIRCULATIONAHA.105.584102 (Pubitemid 43739439)
23. GM Felker JD Leimberger RM Califf MS Cuffe BM Massie KF Adams Jr M Gheorghiade CM O'Connor 2004 Risk stratification after hospitalization for decompensated heart failure J Card Fail 10 6 460 466 15599835 10.1016/j.cardfail.2004.02.011
24. Vazquez R, Bayes-Genis A, Cygankiewicz I, Pascual-Figal D, Grigorian-Shamagian L, Pavon R, Gonzalez-Juanatey JR, Cubero JM, Pastor L, Ordonez-Llanos J, Cinca J, Bayes de Luna A on behalf of the MUSIC Investigators (2009) The MUSIC risk score: a simple method for predicting mortality in ambulatory patients with chronic heart failure. Eur Heart J 30:1088-1096
25. CM O'Connor V Hasselblad RH Mehta G Tasissa RM Califf M Fiuzat JG Rogers CV Leier LW Stevenson 2010 Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score J Am Coll Cardiol 55 9 872 878 20185037 10.1016/j.jacc.2009.08.083
26. MS Oh 2002 Pathogenesis and diagnosis of hyponatremia Nephron 92 Suppl 1 2 8 12401931 10.1159/000065370 1:CAS:528:DC%2BD38Xot1Oit78%3D (Pubitemid 36151475)
27. S Neilsen TH Kwon BM Christensen D Promeneur J Frøkiaer D Marples 1999 Physiology and pathophysiology of renal aquaporins J Am Soc Nephrol 10 647 663 (Pubitemid 29117647)
28. J Penit M Faure S Jard 1983 Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture Am J Physiol 244 E72 E82 6295182 1:CAS:528:DyaL3sXkslOitA%3D%3D
29. GJ Hasking MD Esler GL Jennings D Burton JA Johns PI Korner 1986 Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity Circulation 73 615 621 3948363 10.1161/01.CIR.73.4.615 1:STN:280: DyaL287jsVSltQ%3D%3D (Pubitemid 16081418)
30. GF DiBona PJ Herman LL Sawin 1988 Neural control of renal function in edema-forming states Am J Physiol 254 R1017 R1024 3381907 1:CAS:528: DyaL1cXmt1Oktr0%3D
31. RW Schrier WT Abraham 1999 Hormones and hemodynamics in heart failure N Engl J Med 341 577 585 10451464 10.1056/NEJM199908193410806 1:CAS:528: DyaK1MXlvVOnsbY%3D (Pubitemid 29384167)
32. VL Schuster JP Kokko HR Jacobson 1984 Angiotensin II directly stimulates sodium transport in rabbit proximal convoluted tubules J Clin Invest 73 507 515 6699174 10.1172/JCI111237 1:CAS:528:DyaL2cXhtFGmt78%3D (Pubitemid 14194631)
33. SR Goldsmith 2005 Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure Am J Cardiol 95 9 Suppl 1 B14 B23 10.1016/j.amjcard.2005.03.004 (Pubitemid 40545928)
34. RJ Anderson HM Chung R Kluge RW Schrier 1985 Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin Ann Intern Med 102 164 168 3966753 1:STN:280:DyaL2M%2FpsFemsw%3D%3D (Pubitemid 15157162)
35. CR Lee ML Watkins JH Patterson, et al. 2003 Vasopressin: a new target for the treatment of heart failure Am Heart J 146 9 18 12851603 10.1016/S0002-8703(02)94708-3 1:CAS:528:DC%2BD3sXltF2ju7w%3D (Pubitemid 36851295)
36. PR Kalra SD Anker AJ Coats 2001 Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin Cardiovasc Res 51 495 509 11476740 10.1016/S0008-6363(01)00297-8 1:CAS:528:DC%2BD3MXltlOitrs%3D (Pubitemid 32718598)
37. YJ Xu V Gopalakrishnan 1991 Vasopressin increases cytosolic free [Ca2+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors Circ Res 69 239 245 2054937 1:CAS:528:DyaK3MXlvFyqtrc%3D
38. Y Nakamura T Haneda J Osaki S Miyata K Kikuchi 2000 Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor Eur J Pharmacol 391 39 48 10720633 10.1016/S0014-2999(99)00775-X 1:CAS:528:DC%2BD3cXhslaktr0%3D (Pubitemid 30138078)
39. Y Goldsmith 2006 The role of vasopressin in congestive heart failure Cleve Clin J Med 73 Suppl 3 S19 S23 16970149 10.3949/ccjm.73.Suppl-3.S19
40. DL Xu PY Martin M Ohara, et al. 1997 Upregulation of aquaporin-2 water channel expression in chronic heart failure rat J Clin Invest 99 1500 1505 9119993 10.1172/JCI119312 1:CAS:528:DyaK2sXitlant7c%3D (Pubitemid 27163800)
41. K Nakamura T Aoyagi M Hiroyama S Kusakawa R Mizutani A Sanbe J Yamauchi M Kamohara K Momose A Tanoue 2009 Both (V1A) and (V1B) vasopressin receptors deficiency result in impaired glucose tolerance Eur J Pharmacol 613 1-3 182 188 19375419 10.1016/j.ejphar.2009.04.008 1:CAS:528:DC%2BD1MXms1yisLo%3D
42. SR Goldsmith 2002 Congestive heart failure: potential role of arginine vasopressin antagonists in the therapy of heart failure Congest Heart Fail 8 251 256 12368587 10.1111/j.1527-5299.2002.01158.x 1:CAS:528:DC%2BD38XosFSksbg%3D (Pubitemid 35190548)
43. GS Francis C Benedict DE Johnstone, et al. 1990 Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD) Circulation 82 1724 1729 2146040 10.1161/01.CIR.82.5.1724 1:STN:280:DyaK3M%2FivF2jug%3D%3D (Pubitemid 20367975)
44. JL Rouleau M Packer L Moye, et al. 1994 Prognostic value of neurohormonal activation in patients with an acute myocardial infarction: effect of captopril J Am Coll Cardiol 24 583 591 7915733 10.1016/0735-1097(94)90001-9 1:STN:280:DyaK2czlvValug%3D%3D (Pubitemid 24295729)
45. VL Szatalowicz PE Arnold C Chaimovitz, et al. 1981 Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure N Engl J Med 305 263 266 7242616 10.1056/NEJM198107303050506 1:CAS:528:DyaL3MXltFaqtrs%3D (Pubitemid 11087371)
46. Y Yamane 1968 Plasma ADH level in patients with chronic congestive heart failure Jpn Circ J 32 745 759 5755068 10.1253/jcj.32.745 1:STN:280: DyaF1M%2Fltleiuw%3D%3D
47. SR Goldsmith GS Francis AW Cowley TB Levine JN Cohn 1983 Increased plasma arginine vasopressin levels in patients with congestive heart failure J Am Coll Cardiol 1 1385 1390 6343460 10.1016/S0735-1097(83)80040-0 1:CAS:528: DyaL3sXks1ygurY%3D (Pubitemid 13054124)
48. JG Verbalis SR Goldsmith A Greenberg RW Schrier RH Sterns 2007 Hyponatremia treatment guidelines 2007: expert panel recommendations Am J Med 120 11 Suppl 1 S1 21 17981159 10.1016/j.amjmed.2007.09.001 1:CAS:528: DC%2BD2sXhsVagtbjP (Pubitemid 350027722)
49. C Palm P Gross 1999 2-vasopressin receptor antagonists-mechanism of effect and clinical implications in hyponatraemia Nephrol Dial Transplant 14 2559 2562 10534484 10.1093/ndt/14.11.2559 1:CAS:528:DyaK1MXnvVWqu7k%3D (Pubitemid 32208358)
50. C Palm D Reimann P Gross 2001 The role of V2 vasopressin antagonists in hyponatremia Cardiovasc Res 51 403 408 11476730 10.1016/S0008-6363(01)00288-7 1:CAS:528:DC%2BD3MXltlOisbs%3D (Pubitemid 32718588)
51. M Gheorghiade WA Gattis A Barbagelata, et al. 2003 Rationale and study design for a multicenter, randomized, double-blind, placebo controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure Am Heart J 145 Suppl 2 S51 S54 12594452 10.1067/mhj.2003.154 1:CAS:528:DC%2BD3sXhs1Chtr8%3D (Pubitemid 36207925)
52. LM Burrell J Risvanis CI Johnston, et al. 2000 Vasopressin receptor antagonism-a therapeutic option in heart failure and hypertension Exp Physiol 85 259S 265S 10795930 10.1111/j.1469-445X.2000.tb00031.x 1:CAS:528: DC%2BD3cXjtVOhsrw%3D (Pubitemid 30182289)
53. M Thibonnier P Coles A Thibonnier M Shoham 2001 The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists Annu Rev Pharmacol Toxicol 41 175 202 11264455 10.1146/annurev.pharmtox.41.1.175 1:CAS:528:DC%2BD3MXjsVaqsbc%3D (Pubitemid 32385887)
54. SR Goldsmith 1999 Vasopressin: a therapeutic target in congestive heart failure? J Card Fail 5 347 356 10634676 10.1016/S1071-9164(99)91339-8 1:CAS:528:DC%2BD3cXmsVOitQ%3D%3D (Pubitemid 30033676)
55. F Quittnat P Gross 2006 Vaptans and the treatment of water retaining disorders Semin Nephrol 26 234 243 16713496 10.1016/j.semnephrol.2006.02.003 1:CAS:528:DC%2BD28XlvF2ku7c%3D
56. Package insert (2008) Vaprisol (conivaptan). Astellas Pharma US, Deerfield
57. Package insert (2009) Samsca (tolvaptan). Otsuka America Pharmaceutical, Inc., Rockville
58. CardioKine Inc. THE BALANCE study: treatment of hyponatremia based on Lixivaptan in NYHA class III/IV cardiac patient evaluation. http://www. clinicaltrials.gov
59. D Zeltser S Rosansky H van Rensburg JG Verbalis N Smith Conivaptan Study Group 2007 Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia Am J Nephrol 27 447 457 17664863 10.1159/000106456 1:CAS:528:DC%2BD2sXhtVOrtbzO (Pubitemid 47482001)
60. Annane D, Decaux G, Smith N, for the Conivaptan Study Group (2009) Efficacy and safety of Oral Conivaptan, a Vasopressin-Receptor Antagonist, evaluated in a randomized, controlled trial in patients with Euvolemic or Hypervolemic Hyponatremia. Am J Med Sci 337(1):28-36
61. JK Ghali MJ Koren JR Taylor E Brooks-Asplund K Fan WA Long, et al. 2006 Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia J Clin Endocrinol Metab 91 2145 2152 16522696 10.1210/jc.2005-2287 1:CAS:528:DC%2BD28XlvVCgsL8%3D (Pubitemid 43854997)
62. M Gheorghiade I Niazi J Ouyang, et al. 2003 Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure Circulation 107 2690 2696 12742979 10.1161/01.CIR.0000070422.41439.04 1:CAS:528: DC%2BD3sXjvFKjtbk%3D
63. M Gheorghiade MA Konstam JC Burnett Jr, et al. 2007 Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials JAMA 297 1332 1343 17384438 10.1001/jama.297.12.1332 1:CAS:528:DC%2BD2sXjs1ejt7k%3D (Pubitemid 46513234)
64. WT Abraham AA Shamshirsaz K McFann RM Oren RW Schrier 2006 Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association Functional Class II and III chronic heart failure patient J Am Coll Cardiol 47 8 1615 1621 16630999 10.1016/j.jacc.2005.11.071 1:CAS:528:DC%2BD28XltlCisrg%3D
65. SR Goldsmith M Gheorghiade 2005 Vasopressin antagonism in heart failure J Am Coll Cardiol 46 1785 1791 16286160 10.1016/j.jacc.2005.02.095 1:CAS:528:DC%2BD2MXht1SrtbzO (Pubitemid 41579797)